EASD 2025: GroundBreaking Therapies and New Data Reshape Diabetes Care in Vienna
The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to commence on Monday morning in Vienna, Austria, continuing until Friday, 19 September 2025. As one of the most prominent global scientific gatherings on diabetes, this event presents healthcare providers and specialists with a unique opportunity to stay abreast of the latest advancements in diabetes research and treatment.
The EASD conference has a long-standing reputation for bringing together between 12,000 to 15,000 participants from over 100 countries, ranking it among the world’s largest medical conferences. This year, attendance is expected to exceed 12,000 professionals, including doctors, researchers, and diabetes specialists from across the globe. The meeting melds fundamental research with clinical trials and expert education, spotlighting diabetes, obesity, related complications, and emerging therapies that are reshaping the future of care for these conditions.
Among the highly anticipated research presentations is new data on the drug semaglutide, examining its effects on food noise, body composition, and cardiovascular benefits. Results from the STEP UP trial will also be disclosed, exploring the impact of higher doses of semaglutide on obesity, appetite, muscle strength, and body structure. A head-to-head comparison of the cardiovascular outcomes of Ozempic (semaglutide) versus dulaglutide is expected from the REACH real-world study. Additionally, novel therapies under development by Novo Nordisk, such as cagrilintide and amycretin, will be showcased.
Significant attention is also on the SURPASS-CVOT trial sponsored by Eli Lilly, evaluating the cardiovascular and vascular events of tirzepatide (marketed as Mounjaro/Zepbound) against dulaglutide or Trulicity in patients with type 2 diabetes. These studies underscore the ongoing innovation in drug development and the quest to improve clinical outcomes for diabetes patients.
The event will feature major pharmaceutical players presenting advanced research and product data. Novo Nordisk will highlight new findings related to semaglutide, while Eli Lilly will share insights on tirzepatide for diabetes and obesity management. Sanofi continues to develop long-acting insulins like Toujeo and combined therapies, and Pfizer has entered the field recently with innovative obesity and metabolic disorder treatments.
Esteemed scientists and clinicians, such as Professor Tina Vilsbøll, honorary secretary of the EASD, will contribute to the scientific discourse, sharing comprehensive updates and groundbreaking research developments. This gathering is anticipated to be a crucial platform, revealing new scientific and therapeutic directions likely to have substantial impacts on diabetes and obesity care worldwide.
For executives and leaders in associations and trade bodies within the healthcare sector, the EASD meeting exemplifies how professional collaboration on a global scale drives advances in chronic disease management. The conference not only fosters the dissemination of cutting-edge knowledge but also encourages networking and partnerships essential for enhancing member services in the diabetes care ecosystem. A detailed report covering key recommendations and breakthroughs from the conference will be provided in the upcoming "صحتك" weekly supplement.